Research and Development of HALAVEN(Eribulin Mesylate)

DOI Web Site 9 Citations 40 References

Bibliographic Information

Other Title
  • ハラベン（エリブリンメシル酸塩）の開発研究
  • ハラヴェン(エリブリンメシル酸塩)の開発研究
  • ハラヴェン エリブリンメシル サンエン ノ カイハツ ケンキュウ

Search this article

Description

HALAVENTM (eribulin mesylate, E7389) is a novel anticancer agent discovered and developed by Eisai, which was approved by the United States Food and Drug Administration (FDA) for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. HALAVENTM is a non-taxane, microtubule dynamics inhibitor and a synthetic analog of halichondrin B, a natural product isolated from the marine sponge Halichondria okadai. Although the structure of HALAVENTM is substantially simplified relative to halichondrin B, the development of this complex molecule only by chemical synthesis represents a significant challenge in terms of pharmaceutical development. In this article, a developmental history of HALAVENTM from its discovery to process development aiming at commercial production is described.

Journal

Citations (9)*help

See more

References(40)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top